Elevance (ELV) Q3 2026 Earnings Call Transcript
Elevance Health (ELV) reported strong Q3 2026 results, raising its 2026 adjusted EPS guidance to at least $29 and increasing its 2026 earnings baseline to at least $26.75. The company expects 12% EPS growth in 2027, driven by margin improvements and Carelon's expansion. Medicaid, Medicare Advantage, and Individual ACA segments all performed better than expected, with Carelon's solutions contributing to cost savings and improved outcomes.
How this was made
The 30-second read
Why it matters
The guidance lift is a primary earnings disclosure for a large‑cap insurer, likely prompting a positive market reaction.
Market read
Guidance upgrades for major insurers often drive sector‑wide re‑rating and can move the broader health‑care index.
What to watch
Potential regulatory changes or Medicaid rate pressures could temper the upside.
Background
Elevance Health (formerly Anthem) reported Q3 2026 results, highlighting strong Medicaid, Medicare Advantage, and Individual ACA performance, and issued an upward revision to its 2026 EPS guidance.
Ticker impact
Elevance Health raised its 2026 adjusted diluted EPS guidance to at least $29 and increased its earnings baseline to $26.75, a fresh upward revision disclosed in this earnings call transcript.
upside pressure as investors price in higher EPS expectations
The new guidance exceeds prior expectations and is the first public disclosure, indicating material impact for a large‑cap health insurer.
Market effects
May lift other health insurers and Medicare Advantage providers as analysts reassess sector earnings outlook.
U.S. health‑care sector could see modest gains in the broader market.
Limited to U.S. equities; no direct global macro effect.
Counterpoint
If the guidance assumes optimistic margin improvements that may be hard to sustain, the stock could be overvalued.
Key entities
- companyElevance Health
U.S. health‑insurance provider that issued the guidance raise.
